Crossmark

Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

Crossref DOI link: https://doi.org/10.1186/s13014-021-01941-z

Published Online: 2021-12-02

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hanna, Catherine R. http://orcid.org/0000-0002-0907-7747
O’Cathail, Sean M. http://orcid.org/0000-0001-5574-9199
Graham, Janet S. http://orcid.org/0000-0002-2048-2698
Saunders, Mark

Samuel, Leslie http://orcid.org/0000-0002-8402-8670
Harrison, Mark

Devlin, Lynsey http://orcid.org/0000-0002-4047-0686
Edwards, Joanne

Gaya, Daniel R.

Kelly, Caroline A. http://orcid.org/0000-0002-5330-7888
Lewsley, Liz-Anne

Maka, Noori

Morrison, Paula

Dinnett, Louise

Dillon, Susan http://orcid.org/0000-0002-6676-1393
Gourlay, Jacqueline

Platt, Jonathan J.

Thomson, Fiona http://orcid.org/0000-0002-8987-5369
Adams, Richard A. http://orcid.org/0000-0003-3915-7243
Roxburgh, Campbell S. D. http://orcid.org/0000-0002-2649-6695
License Information

Text and Data Mining valid from 2021-12-01

Version of Record valid from 2021-12-02
More Information

Article History

First Online: 2 December 2021